Incyte gets green light for new eczema cream – and a warning
A topical version of Incyte's eczema drug ruxolitnib has passed through the eye of the needle at the FDA, but a warning has been issued regarding its drug class.
by elizabeth mønsted johansen, translated by catherine brett
After an extended assessment period, the FDA has ruled on Incyte's topical formulation of eczema treatment ruxolitnib.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi's big dermatology hope fails in phase III
For subscribers
.jpg&w=384&q=75)
